

1 DEBRA J. CARFORA  
JOHN THOMAS H. DO  
2 BRANDON N. ADKINS  
3 U.S. Department of Justice  
Environmental Defense Section  
4 P.O. Box 7611  
Washington, D.C. 20044  
5 Tel: (202) 514-2640  
6 Fax: (202) 514-8865  
Email: debra.carfora@usdoj.gov

7 *Attorneys for Defendants*

8  
9 **UNITED STATES DISTRICT COURT**  
10 **NORTHERN DISTRICT OF CALIFORNIA**  
11 **SAN FRANCISCO DIVISION**

12 FOOD & WATER WATCH, INC., et al.,

13 Plaintiffs,

14 v.

15 U.S. ENVIRONMENTAL PROTECTION  
AGENCY, et al.,

16 Defendant.

Case No. 17-CV-02162 EMC

**DEFENDANTS' REPLY IN SUPPORT  
OF THEIR MOTION FOR  
SUMMARY JUDGMENT**

Date: November 7, 2019

Time: 12:00 p.m.

Place: Courtroom 5, 17th floor

**TABLE OF CONTENTS**

1

2 TABLE OF AUTHORITIES ..... iii

3 INTRODUCTION ..... 1

4 ARGUMENT ..... 1

5 I. TSCA Risk Determinations Require Systematic Review ..... 1

6 II. Plaintiffs Have Not Proffered Evidence to Demonstrate Unreasonable Risk..... 5

7 III. Plaintiffs Failed to Show that Studies Conducted in Mexico and Canada are

8 Generalizable to the United States..... 9

9 IV. Plaintiffs Cannot Bring This Case About Neurotoxic Harm Because They Face

10 No Credible Threat of Neurotoxic Harm. .... 11

11 A. TSCA Section 21 Petition Denials May Be Challenged Only By Those

12 Who Suffer the Purported Unreasonable Risk..... 11

13 B. Plaintiffs Lack Article III Standing..... 13

14 CONCLUSION..... 15

**TABLE OF AUTHORITIES**

**Cases**

*Air Wis. Airlines Corp. v. Hoeper*,  
571 U.S. 237 (2014)..... 2

*Anderson v. Liberty Lobby, Inc.*,  
477 U.S. 242 (1986)..... 1

*Dep’t of Transp. v. Pub. Citizen*,  
541 U.S. 752, (2004)..... 12

*Ethyl Corp. v. U.S. Environmental Protection Agency*,  
541 F.2d 1 (D.C. Cir. 1976)..... 6, 7

*Food & Water Watch, Inc. v. EPA*,  
291 F. Supp. 3d 1033 (N.D. Cal. 2017)..... 2, 3

*Food & Water Watch, Inc. v. EPA*,  
302 F. Supp. 3d 1058 (N.D. Cal. 2018)..... 4, 11, 12

*Hernandez v. Williams, Zinman & Parham PC*,  
829 F.3d 1068 (9th Cir. 2016) ..... 3, 4

*Lujan v. Defenders of Wildlife*,  
504 U.S. 555 (1992)..... 15

*Mossville Envtl. Action Now v. EPA*,  
370 F.3d 1232 (D.C. Cir. 2004)..... 12

*Northside Sanitary Landfill, Inc. v. Thomas*,  
849 F.2d 1516 (D.C. Cir. 1988)..... 12

*Pennsylvania v. New Jersey*,  
426 U.S. 660 (1976)..... 13

*San Diego Cty. Gun Rights Comm. v. Reno*,  
98 F.3d 1121 (9th Cir. 1996) ..... 15

*Sanders v. City of Fresno*,  
551 F. Supp. 2d 1149 (E.D. Cal. 2008), *aff’d*, 340 F. App’x 377 (9th Cir. 2009)..... 6, 11

*Summers v. Earth Island Inst.*,  
555 U.S. 488 (2009)..... 12

1 *Taylor v. List*,  
 2 880 F.2d 1040 (9th Cir. 1989) ..... 14

3 *United Food & Commercial Workers Union Local 751 v. Brown Group, Inc.*,  
 4 517 U.S. 544 (1996)..... 3

5 *United States v. Mohrbacker*,  
 6 182 F.3d 1041 (9th Cir. 1999) ..... 3

7 *Wash. Envtl. Council v. Bellon*,  
 8 732 F.3d 1131 (9th Cir. 2013) ..... 15

9

10 **Statutes**

11 15 U.S.C. § 2605(b)(4)(A) ..... 1

12 15 U.S.C. § 2605(b)(4)(F)..... 2

13

14 15 U.S.C. § 2620(b)(4)(A) ..... 11

15 15 U.S.C. § 2620(b)(4)(B)(ii) ..... 1

16 15 U.S.C. § 2620(h) ..... 2

17 15 U.S.C. § 2620(i) ..... 2

18

19 15 U.S.C. § 2625 ..... 4

20 15 U.S.C. § 2625(h) ..... 4, 7, 8

21 15 U.S.C. § 2625(i) ..... 4, 8

22 15 U.S.C. §2625(l)(2) ..... 4

23

24 15 U.S.C. § 2625(l)(5) ..... 3

25

26 **Rules**

27 Fed. R. Evid. 801 ..... 14

28 Fed. R. Evid. 805 ..... 8

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**Legislative Materials**

162 Cong. Rec. S3517 (daily ed. June 7, 2016)..... 2  
162 Cong. Rec. S3518 (daily ed. June 7, 2016)..... 2, 4, 5  
H.R. Rep. No. 114-176 (2015)..... 2, 4, 6

**Federal Register**

82 Fed. Reg. 33,726 (July 20, 2017)..... 4, 7, 8

## INTRODUCTION

1  
2 In moving for summary judgment, EPA explained that Plaintiffs failed to employ the  
3 science standards and data-quality considerations required by TSCA to support a finding that the  
4 addition of fluoridation chemicals to drinking water up to the recommended concentration of  
5 0.7 mg/L poses an unreasonable risk of neurotoxic effects. Plaintiffs implicitly acknowledge this  
6 failure in their response, arguing that because TSCA’s risk-evaluation process and scientific  
7 standards provisions are not set forth in section 21, the Court may make a finding of “unreasonable  
8 risk” under section 21 completely unconstrained by the text and structure of the statute and  
9 congressional intent. Plaintiffs are wrong. In addition to failing to satisfy the statutorily required  
10 *process, criteria, and standards* for determining risk, there have been no published  
11 epidemiological studies measuring fluoride’s potential neurotoxic effects in the United States.  
12 Plaintiffs instead ask the Court to assume, without support, that prenatal maternal urinary-fluoride  
13 concentrations in the United States must be similar to those observed in samples studied in Canada  
14 and Mexico City. Finally, Plaintiffs are not within the zone-of-interests of TSCA and lack  
15 Article III standing. The Court should grant EPA’s Motion for Summary Judgment.

## ARGUMENT

### I. TSCA RISK DETERMINATIONS REQUIRE SYSTEMATIC REVIEW.

17  
18 In deciding a motion for summary judgment, the substantive law identifies which facts are  
19 material to the dispute. *Anderson v. Liberty Lobby, Inc.*, 477 U.S. 242, 248 (1986). Here, the  
20 substantive legal *process, criteria, and standards* for determining whether a chemical substance  
21 “presents an unreasonable risk of injury to health or the environment, without consideration of  
22 costs or other nonrisk factors, including an unreasonable risk to a potentially exposed or  
23 susceptible subpopulation, under the conditions of use,” 15 U.S.C. § 21(b)(4)(B)(ii), are set forth  
24 in TSCA section 6(b)(4)(B) and (F) and section 26(h) and (i). Section 6(b)(4)(B) requires a risk  
25 evaluation *process*, section 6(b)(4)(F) sets forth *criteria* that must be used in conducting a risk  
26 evaluation, section 26(h) requires that in carrying out section 6, decisions based on science be  
27 employed in a manner consistent with the best available science, and section 26(i) requires that *all*  
28 section 6 decisions be based on the weight of the scientific evidence. 15 U.S.C. § 2605(b)(4)(A),

1 (F), § 2620(h), (i). Congress made clear that under modern risk assessment principles, “[t]he term  
2 ‘weight of the evidence’ refers to a systematic review method.” See 162 Cong. Rec. S3518 (daily  
3 ed. June 7, 2016); H.R. Rep. No. 114-176, at 33 (2015). Thus, despite Plaintiffs’ insistence to the  
4 contrary, TSCA *does* require the application of a systematic review method for determining risk,  
5 as a matter of law.

6 *First*, Plaintiffs’ burden to show “unreasonable risk” under section 21(b)(4)(B)(ii) tracks  
7 nearly verbatim the standard for risk-evaluation in section 6(b), signifying that those concepts  
8 should be consistently construed. See EPA Opp’n 6, ECF No. 119; *Air Wis. Airlines Corp. v.*  
9 *Hooper*, 571 U.S. 237, 248 (2014) (“It is a cardinal rule of statutory construction that, when  
10 Congress employs a term of art, it presumably knows and adopts the cluster of ideas that were  
11 attached to each borrowed word in the body of learning from which it is taken.” (internal quotation  
12 marks omitted)). And because section 21 is one of three “pathways” to a section 6(a) rule, see  
13 *Food & Water Watch, Inc. v. EPA (“F&WW I”)*, 291 F. Supp. 3d 1033, 1046 (N.D. Cal. 2017),  
14 the substantive requirements for demonstrating an unreasonable risk are “the ‘facts’ that would  
15 establish the existence of ‘an unreasonable risk’ under Section 6(a).”<sup>1</sup> *Id.* at 1045. Thus, the Court’s  
16 consideration of risk must be based on the *process, criteria, and standards* that Congress made  
17 integral to determining whether regulation is warranted under section 6(a). See also EPA Br. 4–6;  
18 EPA Opp’n 5.

19 Further supporting this statutory construction is that Congress intended for EPA to rely on  
20 “the conclusions regarding . . . effects and exposures of the chemical in the risk evaluation itself”  
21 in determining how to regulate unreasonable risks. 162 Cong. Rec. S3517 (daily ed. June 7, 2016).

---

22  
23 <sup>1</sup> If a determination of unreasonable risk to health is made pursuant to subsection (b)(4)(A),  
24 “then a regulation to address that risk is warranted under section 6(a), and the Administrator  
25 must proceed to section 6(a) rulemaking.” H.R. Rep. No. 114-176, at 23. In other words, “section  
26 6(b) generally prohibits EPA from restricting a chemical substance before making this  
27 determination based on the findings of the risk evaluation.” *Id.* at 24. “[W]hile the phrase  
28 ‘unreasonable risk of injury’ [was] not amended [in the Frank R. Lautenberg Chemical Safety for  
the 21st Century Act], it must be read in the context of the changes to section 6, including the  
functions and purposes delineated in subsections (a), (b), and (c).” *Id.* at 28. “Unreasonable risk”  
must be construed under section 21 in light of the overall statutory scheme and congressional  
intent.

1 If the Court were to make a finding of unreasonable risk independent of the statutory standards for  
2 doing so, EPA could be put in the untenable position of making scientific judgments in the  
3 section 6(a) risk-management rule that are not supported by the best available science or weight  
4 of the scientific evidence as required by section 26(h) and (i). *See* EPA Br. 8. As evidence that  
5 Congress intended to avoid such a result, Congress required EPA to develop guidance setting forth,  
6 at a minimum, the “quality of the information submitted and the process to be followed in  
7 developing draft risk evaluations” to “assist interested persons in developing and submitting draft  
8 risk evaluations.” 15 U.S.C. § 2625(l)(5); *see* EPA Br. 7–9. To wholly set aside the guidance would  
9 render section 26(l)(5) superfluous. “[T]he more natural reading of the statute’s text, which would  
10 give effect to all of its provisions, always prevails over a mere suggestion to disregard or ignore  
11 duly enacted law as legislative oversight.” *United Food & Commercial Workers Union Local 751*  
12 *v. Brown Group, Inc.*, 517 U.S. 544, 550 (1996); *United States v. Mohrbacker*, 182 F.3d 1041,  
13 1050 (9th Cir. 1999) (same).

14 Plaintiffs’ out-of-context quotations from this Court’s prior order do not support their  
15 argument that the substantive requirements of the statute do not apply to the Court’s determination  
16 of risk under section 21. Pls.’ Opp’n 17–18, ECF No. 120. In denying EPA’s motion to dismiss,  
17 the Court declined to find that the full extent of conditions of use included in a risk evaluation  
18 under section 6(b) must also be included in a section 21 petition. *F&WW I*, 291 F. Supp. 3d at  
19 1052. The Court compared the petition provision with the judicial-review provision of section 21,  
20 which “specifically identifies Section 6(a), suggesting that Section 6(a) (and not Section 6(b)  
21 discussing risk evaluations) is the only provision of Section 6 which pertains to citizen petitions.”  
22 *Id.* Here, the construction of the statute put forward by EPA in its opening brief harmonizes  
23 section 21’s judicial-review provision with TSCA’s statutory scheme. *See Hernandez v. Williams,*  
24 *Zinman & Parham PC*, 829 F.3d 1068, 1073 (9th Cir. 2016).

25 *Second*, even if the Court were to set aside the section 6(b) *process* and *criteria*  
26 requirements that must inform section 6(a) rulemaking, TSCA section 26 sets forth the scientific  
27 standards for “making decisions” and “carrying out” section 6. 15 U.S.C. § 2625; *Hernandez*, 829  
28 F.3d at 1073; EPA Br. 7. Section 26 requires that in carrying out section 6, decisions based on



1 science *shall* be consistent with the best available science and that *all* decisions *shall* be based on  
2 the weight of the scientific evidence. EPA Br. 7–9. Here, the Court’s unreasonable-risk  
3 determination will be a science-based decision. *Food & Water Watch, Inc. v. EPA* (“*F&WW II*”),  
4 302 F. Supp. 3d 1058, 1070 (N.D. Cal. 2018) (“Given the elements of the claim . . . , [the evidence]  
5 should be focused on scientific evidence and expert discovery regarding the risk of injury to health  
6 or the environment posed by the chemical substances at issue in Plaintiffs’ petition.”). Therefore,  
7 Plaintiffs must demonstrate that their evidence meets the statutory standards for section 6 decision  
8 making, including best available science and weight of the scientific evidence under section 26(h)  
9 and (i).<sup>2</sup> 15 U.S.C. §§ 2625(h), (i); *see* EPA Br. 5, 8.

10 “Weight of scientific evidence means a systematic review method . . . .” 82 Fed. Reg.  
11 33,748 (July 20, 2017); 162 Cong. Rec. S3518 (daily ed. June 7, 2016). Plaintiffs’ suggestion that,  
12 because EPA defined “weight of the scientific evidence” by regulation, Congress did not require  
13 “systematic review” under TSCA, is misleading. Pls.’ Opp’n 17. In fact, EPA adopted verbatim  
14 Congress’ definition of weight of the scientific evidence.<sup>3</sup> *See* 162 Cong. Rec. S3518 (daily ed.  
15 June 7, 2016); H.R. Rep. No. 114–176, at 33; EPA Br. 13–14. Thus, because Plaintiffs’ experts  
16 cannot support their opinions with a systematic review, Plaintiffs’ claim fails as a matter of law.

17 Plaintiffs’ reliance on EPA’s experts’ systematic reviews to identify the best available  
18 science does not save their claim. To begin with, Plaintiffs’ argument that EPA’s systematic  
19 reviews place before the Court the best available science misses the point entirely. Systematic  
20 review requires more than the collection of scientific studies; rather, it is necessary to document a

---

21 <sup>2</sup> Although this argument assumes, *arguendo*, that Plaintiffs are not required to satisfy the  
22 *process* and *criteria* requirements in section 6(b)(4), Plaintiffs appear to concede that at least  
23 some risk-assessment process must be used to meet their burden under section 21(b)(4)(B)(ii).  
24 *See* Pls.’ Opp’n 2–4 (explaining the first two steps in risk assessments and EPA’s general use of  
25 the 1998 Guidelines for Neurotoxicity Risk Assessment). Because section 26 governs the  
26 standards for decisions making under section 6, the scientific standards and weight of the  
27 scientific evidence requirements in sections 26(h) and (i) apply to each step of whatever risk-  
28 assessment process Plaintiffs may use to justify a finding of unreasonable risk under section 21.

<sup>3</sup> Although Congress defined the term “weight of the evidence” under modern day risk  
assessment principles, Congress did not include that definition in the statute to preserve EPA’s  
ability to redefine that term as “necessary to reflect new scientific developments or  
understandings.” *See* 15 U.S.C. §2625(l)(2).

1 comprehensive and transparent process for ensuring consistency in the results and objectivity in  
2 employing scientific judgment throughout the entire risk-assessment process. Even if Plaintiffs’  
3 experts found the same studies as EPA’s experts,<sup>4</sup> Plaintiffs’ experts failed to systematically  
4 integrate the “evidence as necessary and appropriate based upon strengths, limitations, and  
5 relevance.” 162 Cong. Rec. S3518 (daily ed. June 7, 2016); *see* EPA Br. 14–18. This integration  
6 is required by law, but it is also essential for offering credible scientific opinions on risk.

7 The only opinion of record based on Dr. Ellen Chang’s systematic review of  
8 epidemiological studies and Dr. Joyce Tsuji’s systematic review of the toxicological studies is that  
9 of Dr. Tala Henry, EPA’s risk-assessment expert. Dr. Henry opined that “based on Dr. Tsuji’s and  
10 Dr. Chang’s expert review and evaluation of the body of literature . . . sufficient information is not  
11 reasonably available at this time to integrate information on hazards and exposures into a risk  
12 characterization, a necessary step for reaching a determination of risk under *any* risk assessment  
13 process.” Second Henry Decl. ¶ 8 (Oct. 23, 2019) (emphasis added), Exhibit A.

14 *Third*, Plaintiffs’ argument that “EPA’s own conduct” is evidence of the legal standard in  
15 this case is nonsensical. Pls.’ Opp’n 18. To begin with, Plaintiffs, not EPA, must demonstrate by  
16 a preponderance of the evidence that adding fluoridation chemicals to drinking water poses an  
17 unreasonable risk. *See* EPA Opp’n 4–7. Moreover, Plaintiffs concede that EPA’s epidemiology  
18 and toxicology experts *did* conduct systematic reviews, upon which Plaintiffs now seek to rely in  
19 light of their failure to put forward evidence that meets TSCA’s minimum scientific requirements.  
20 Thus, because the opinions offered by Plaintiffs’ experts Drs. Kathleen Thiessen and Philippe  
21 Grandjean are unsupported by section 26’s substantive requirements for carrying out and making  
22 decisions under section 6, Plaintiffs’ claim fails as a matter of law.

23 **II. PLAINTIFFS HAVE NOT PROFFERED EVIDENCE TO DEMONSTRATE  
24 UNREASONABLE RISK.**

25 Plaintiffs point to Dr. Thiessen’s Margin-of-Exposure (“MOE”) analysis and  
26 Dr. Grandjean’s Benchmark Dose (“BMD”) analysis as evidence of unreasonable risk. Pls.’  
27 Opp’n 12–13. While it is true that in conducting TSCA risk evaluations, EPA *generally* uses an

28 <sup>4</sup> Plaintiffs’ assertion that their experts did not miss studies because of their failure to  
conduct a systematic search of the literature is plainly contradicted by the record. EPA Br. 16.

1 MOE approach to characterize risk, *any* approach for characterizing risk is only as good as the  
2 assumptions made and the data (or information) used in the calculation. Here, because  
3 Drs. Thiessen and Grandjean failed to (1) demonstrate that their analyses are based on information  
4 consistent with its intended use, as required by section 26(h) and (i) and (2) demonstrate a  
5 scientifically sound integrative analysis based on the preceding components of the risk assessment,  
6 as required by section 6(b) and risk-assessments generally, the Court lacks a factual predicate from  
7 which an inference of unreasonable risk can be drawn. *See Sanders v. City of Fresno*, 551 F. Supp.  
8 2d 1149, 1163 (E.D. Cal. 2008), *aff'd*, 340 F. App'x 377 (9th Cir. 2009) (explaining that in ruling  
9 on a motion for summary judgment, inferences are not drawn out of the air, and it is the opposing  
10 party's obligation to produce a factual predicate from which the inference may be drawn); EPA  
11 Br. 9; EPA Opp'n 11–13.

12 To begin with, neither the legislative history, case law, nor Dr. Henry's testimony support  
13 the application of the "significant risk" or "unacceptable risk" standard advanced by Plaintiffs.  
14 Notably, in support of the argument that Congress envisioned the standard for judging risk under  
15 TSCA to be "significant risk," Plaintiffs cite the discussion of *section 6 standards* in the July 14,  
16 1976 House Report on the Toxic Substances Control Act. Pls.' Opp'n 11–12. Plaintiffs thus  
17 concede that the Court should apply *section 6 standards* for determining risk. *See supra* Part I. But  
18 by relying on the pre-amendment legislative history, Plaintiffs ask the Court to ignore that the 2016  
19 TSCA amendments made "substantive, clarifying, and structural changes to TSCA section 6,"  
20 including section 6(a). H.R. Rep. No. 114–176, at 23.

21 Next, in support of the argument that courts apply "significant risk" as the standard for  
22 judging risk under TSCA, Plaintiffs cite *Ethyl Corp. v. U.S. Environmental Protection Agency*,  
23 541 F.2d 1 (D.C. Cir. 1976), which involved a challenge to an EPA rulemaking pursuant to a Clean  
24 Air Act ("CAA") provision that authorized regulation of gasoline additives whose emission  
25 products "will endanger" the public health or welfare. The "significant risk of harm" standard  
26 applied in that case was based on EPA's interpretation of the CAA, not the court's. 541 F.2d at 12.

27 Finally, Plaintiffs attempt to rely on Dr. Henry's testimony to suggest that EPA determines  
28 risk solely on an MOE calculation. Pls.' Br. 17, ECF No. 117. As Dr. Henry testified, however,

1 the MOE is a “starting point” for the risk-determination step required under the amended TSCA.  
2 Henry Dep. 270:20–271:13; 298:3–19; *see also* 82 Fed. Reg. 33,735 (listing factors EPA may  
3 weigh in making a risk determination as the final step of the risk-evaluation process). Thus, the  
4 MOE does not on its own constitute a finding of “unreasonable risk” under TSCA.

5 EPA explained why the deficiencies in the analyses of Drs. Thiessen and Grandjean require  
6 judgment in favor of EPA, EPA Opp’n 7–14, and will not reiterate those reasons here, except to  
7 note that Plaintiffs do not dispute *three* material facts that are fatal to their claim.

8 *First*, Plaintiffs do not dispute that “Dr. Thiessen found unacceptable risks for every point  
9 of departure that can be justified from the *animal literature . . .*” Pls.’ Opp’n 12 (emphasis added);  
10 Thiessen Decl. ¶¶ 6–7. Neither do Plaintiffs dispute—nor could they—that the best available  
11 science for conducting a dose-response assessment is the human epidemiological data. *See* Thayer  
12 Dep. 56:9–19 (May 17, 2019) (“[A]fter an assessment, at the end of the day if you felt like you  
13 had epidemiological data that had the right features to lend themselves for dose-response, you  
14 would explore that first; *id.* at 149:19–25 (“[I]f we have that information that shows humans suffer  
15 harm, then . . . that would be our first line of evidence . . .”). Because Dr. Thiessen did not assess  
16 a dose response “consistent with the best available science,” her MOE analysis cannot be used to  
17 support a finding of unreasonable risk under TSCA. 15 U.S.C. § 2625(h); EPA Opp’n 14.

18 *Second*, Plaintiffs do not dispute Dr. Grandjean’s failure to “actually calculate[] the  
19 BMDs.” Pls.’ Opp’n 13. Plaintiffs’ characterization of Dr. Grandjean’s admission as a “fleeting  
20 moment of levity” is not credible in light of the importance of the BMD calculation nor does it  
21 make up for the lack of a factual predicate from which the Court could infer risk. *See* EPA Br. 14;  
22 EPA Opp’n 11–13. In other words, the Court cannot assume that the BMD offered by  
23 Dr. Grandjean identifies a threshold dose at which effects may be seen, especially where, as here,  
24 the calculation fails to include a material translation from fluoride urinary concentration (which is  
25 correlated to the IQ response) back to a fluoride water concentration. *E.g.*, Henry Dep. 354:13–  
26 355:5.

27 *Third*, Plaintiffs do not dispute that Dr. Grandjean failed to “calculate a specific exposure  
28 limit.” Grandjean Decl. ¶ 8; Pls.’ Opp’n 13. Thus, Dr. Grandjean omitted two steps in the risk-

1 assessment process required under TSCA. Whether under the 1998 Guidelines or the Risk  
2 Evaluation Rule, risk assessment requires that risk characterization (here, the MOE approach) be  
3 based on an actual dose-response assessment and exposure assessment. *See* Pls.’ Opp’n 2–3  
4 (discussing risk-assessment steps); *see also* Tala Decl. ¶¶ 17–20. Instead, Plaintiffs offer  
5 inadmissible double-hearsay to assert that “the BMDL [benchmark dose level] values that [Dr.  
6 Grandjean] calculated are well below the exposure levels that have been documented in fluoridated  
7 communities in North America.” Grandjean Decl. ¶ 8.<sup>5</sup> In addition, because Dr. Grandjean did not  
8 conduct a systematic review, the Court cannot assume that the referenced studies, if at all, are  
9 “consistent with” or “relevant for” calculating exposure. *See* 15 U.S.C. § 2625(h), (i); EPA Opp’n  
10 11–13.

11 Because Dr. Thiessen did not assess a dose response using the human data, “consistent  
12 with the best available science,” and, because Plaintiffs ask the Court to assume that  
13 Dr. Grandjean’s BMD level is below the levels of exposure to fluoridated water programs in the  
14 United States, Plaintiffs fail to offer the factual predicate necessary to support a risk  
15 characterization and, thus, their claim fails as a matter of law.

16 EPA is also entitled to judgment as a matter of law because Plaintiffs did not complete all  
17 of the risk-assessment steps, which are required to provide the factual predicate for the Court to  
18 weigh evidence-based conclusions. *See* 82 Fed. Reg. 33,734–35; Henry Decl. ¶ 23; EPA Opp’n 2–  
19 3. For example, none of Plaintiffs’ experts completed an exposure assessment. *See* EPA’s  
20 Opp’n 14 (discussing Dr. Thiessen’s assumptions); *id.* at 9 n.7 (discussing Dr. Grandjean’s  
21 assumptions). Even if Plaintiffs were not required to demonstrate each of the substantive risk-  
22 evaluation steps under section 6(b)(4), their claim still fails as a matter of law because Plaintiffs  
23 concede that to meet their burden here, risk must be assessed using *some* risk-assessment process.  
24 *See supra* note 2.

25  
26  
27 <sup>5</sup> Dr. Grandjean relies upon his own reports to support his assertion. His expert reports  
28 constitute the first layer of inadmissible hearsay. *See* EPA Opp’n 10 n.8. The references within  
his expert reports are the second layer of inadmissible hearsay. *See* Fed. R. Evid. 805.

1           **III.           PLAINTIFFS FAILED TO SHOW THAT STUDIES CONDUCTED IN MEXICO**  
2           **AND CANADA ARE GENERALIZABLE TO THE UNITED STATES.**

3           Plaintiffs' expert, Dr. Grandjean, relied on studies conducted in Mexico and Canada to  
4 support his assertion that fluoride is a developmental neurotoxin at levels consistent with exposure  
5 in the U.S. population. EPA Br. 12. However, Plaintiffs failed to point to evidence to support a  
6 series of assumptions they made to conclude that the results of those studies are generalizable to  
7 the United States. *See id.* at 12–14.

8           Dr. Howard Hu testified that the fluoride concentrations in prenatal maternal urine—a  
9 biomarker used to estimate total fluoride exposure—collected from mothers in Mexico City in one  
10 project were within the range of urinary fluoride concentrations of pregnant women in Canada for  
11 a different project. Hu Dep. 31:23–32:11. This comparison, however, has nothing to do with any  
12 population in the United States. Rather, Plaintiffs rely on a vague statement that Canadians and  
13 Americans are, “biologically speaking,” similar, Pls.' Opp'n 15 (citing Lanphear Dep. 58:20–23),  
14 and assume that prenatal maternal urine concentrations in the United States must be similar to  
15 those observed in a sample studied in Canada. Pls.' Opp'n 15. But even statements from Plaintiffs'  
16 experts' publications explain that data are not available for such a comparison. *See* EPA Br. 13.

17           Plaintiffs then further assume without support that the overlapping range of maternal  
18 urinary fluoride concentrations observed in the Mexico City and Canada populations studied  
19 shows that those populations experience the same total fluoride exposure and, further still, that the  
20 U.S. population must also experience the same fluoride exposure. Yet Plaintiffs acknowledge that  
21 the source of fluoride exposure differs across Mexico and Canada. In Mexico, the main source of  
22 fluoride exposure is salt, and in Canada, water. *See* Pls.' Opp'n 15. Dr. Hu could not say whether  
23 or not the source of fluoride exposure influences observed fluoride concentrations in the urine of  
24 pregnant women. Hu Dep. 91:13–20; *id.* at 128:14–21. Nor was Dr. Hu aware of any studies  
25 measuring whether or not the source of exposure could influence fluoride concentrations in  
26 maternal urinary biomarkers. *Id.* at 92:6–7. Dr. Hu further testified that a comparison of fluoride  
27 biomarkers across populations with different sources of exposure could not support inferences  
28

1 regarding external exposures. *Id.* at 97:5–9; *id.* 132:24–133:1 (“I think that our data just simply  
2 don’t allow us to infer anything about fluoride intake for a variety of reasons.”).<sup>6</sup>

3 In a last-ditch effort, Plaintiffs point to Dr. Grandjean’s tenuous statement that the  
4 relatively higher rate of dental fluorosis (a condition associated with fluoride consumption) and  
5 reach of water fluoridation in the United States “suggests” that urine fluoride concentrations in the  
6 United States “may be higher than in Canada.” Pls.’ Opp’n 15–16 (quoting Grandjean Report 15).  
7 This statement does not support the assumptions Plaintiffs make. Moreover, Plaintiffs’ selective  
8 quote from Dr. Grandjean’s report,<sup>7</sup> ignores his further statement that the “lack of large and  
9 representative studies on fluoride concentrations in urine . . . makes it hard to judge the overall  
10 fluoride exposure levels in U.S. populations.” Grandjean Report 15, EPA Br. Ex. 5. In any event,  
11 Dr. Grandjean’s assertion of what “might” be cannot satisfy Plaintiffs’ burden to support their  
12 assertions with evidence. Finally, Dr. Grandjean’s statement in his rebuttal report that he is  
13 “aware” of an unpublished manuscript that he claims is a fluoride exposure assessment in  
14 California, wherein the “maternal urinary fluoride concentrations were similar to those reported  
15 from Canada,” does not satisfy Plaintiffs’ burden here. Dr. Grandjean failed to explain in any  
16 meaningful way how the analyses and methodologies used to collect and analyze fluoride  
17 concentrations in urine samples in the unpublished manuscript are comparable to the Canadian  
18 cohort studies. And even if they were comparable, Dr. Grandjean’s assertion still leaves Plaintiffs’  
19 assumptions regarding the source of exposure across the populations unsupported. Therefore,  
20 Plaintiffs failed to provide evidentiary support for each of the logical leaps they make to assert that  
21  
22  
23

---

24 <sup>6</sup> Dr. Hu even acknowledged that the source of exposure could have “public health  
25 ramifications,” because one “need[s] to know something about the absorption rates, etc. to  
26 understand how much fluoride is advisable in either salt or water”; “[u]ltimately, that will  
determine what your internalized exposure is to fluoride.” Hu Dep. 92:23–93:5.

27 <sup>7</sup> For the reasons stated in EPA’s Opposition, EPA objects to Plaintiffs’ reliance on  
28 Dr. Grandjean’s expert reports and a podcast, Pls.’ Opp’n 16, as inadmissible hearsay. EPA  
Opp’n 10 n.8.



1 studies conducted in Mexico and Canada are generalizable to the United States.<sup>8</sup> *See Sanders*, 551  
2 F. Supp. 2d at 1163.

3 **IV. PLAINTIFFS CANNOT BRING THIS CASE ABOUT NEUROTOXIC HARM**  
4 **BECAUSE THEY FACE NO CREDIBLE THREAT OF NEUROTOXIC HARM.**

5 Plaintiffs argue that fluoridation chemicals in drinking water result in neurotoxic harm,  
6 particularly in reducing IQ. It is not unreasonable to ask: who among Plaintiffs suffers from this  
7 claimed threat of neurotoxic harm? Plaintiffs' best response is that Julie Simms claims to have  
8 experienced headaches during the time she consumed fluoridated water. Pls.' Opp'n 22. Plaintiffs  
9 never before claimed that headaches are an unreasonable risk, and they have not shown that  
10 fluoridated drinking water causes headaches, much less that there is a genuine dispute of fact.

11 **A. TSCA Section 21 Petition Denials May Be Challenged Only By Those Who**  
12 **Suffer the Purported Unreasonable Risk.**

13 Plaintiffs and Defendants agree: to fall within the zone-of-interests of a statute, Congress  
14 must have intended the litigant be able to seek judicial review. TSCA limits the availability of  
15 judicial review to those who first petition EPA. 15 U.S.C. § 2620(b)(4)(A). Plaintiffs must explain  
16 the "facts" that establish the "unreasonable risk" to EPA in their petition, and these facts will  
17 "frame" any case Plaintiffs may bring. *See F&WW II*, 302 F. Supp. 3d at 1069–70. Plaintiffs  
18 identified neurotoxic harm as the only unreasonable risk in the petition and have focused on the  
19 neurotoxic impacts *in utero* and on infants. *See* Pls' Br. 13–14. But none of the Plaintiffs is  
20 pregnant, a potential parent, or an infant, nor can any otherwise claim to have suffered neurotoxic  
21 harm. EPA Br. Part II(A). Plaintiffs agree that they must show an unreasonable risk of neurotoxic  
22 harm, but seem to contend that they can seek judicial review regarding the purportedly  
23 unreasonable risk of neurotoxic harm without demonstrating any threat of risk themselves. This  
24 argument has no basis in TSCA. Only those at risk may sue the federal government for redress.  
25 *Summers v. Earth Island Inst.*, 555 U.S. 488, 495–96 (2009). Plaintiffs primarily argue that they

---

26  
27 <sup>8</sup> Plaintiffs' attempt to flip the burden on EPA is without support. *See* Pls.' Opp'n 15  
28 (explaining that EPA's brief did not identify a reason why Americans exposed to community  
water fluoridation will have less fluoride exposure).



1 presented headaches as an unreasonable risk to EPA, and that two of their declarants are at risk of  
2 this harm. This alternative argument is incorrect for several reasons.

3 *First*, Plaintiffs did not once mention “headaches” in their petition. Plaintiffs claim that  
4 they did petition EPA on the alleged unreasonable risk of headaches because they attached a single  
5 study to their petition that discussed headaches as one symptom participants reported from  
6 drinking fluoridated water. Attaching one study, among over three hundred others, that discusses  
7 self-reported headaches as a symptom without actually naming “headaches” as a risk in the petition  
8 is not sufficient to identify this risk in the petition. *See Dep’t of Transp. v. Pub. Citizen*, 541 U.S.  
9 752, 764–65, (2004) (A bedrock of administrative law is “alert[ing] the agency to the [parties’]  
10 position and contentions in order to allow the agency to give the issue meaningful consideration.”);  
11 *Mossville Envtl. Action Now v. EPA*, 370 F.3d 1232, 1238 (D.C. Cir. 2004) (An attachment to a  
12 comment letter that “does not directly address” an issue does not alert an agency with “reasonable  
13 specificity.”); *Northside Sanitary Landfill, Inc. v. Thomas*, 849 F.2d 1516, 1519 (D.C. Cir. 1988)  
14 (agency need not divine why a fact buried in eleven attachments is relevant to a rulemaking). EPA  
15 cannot be expected to scour every attachment to identify every risk not mentioned in a petition.

16 *Second*, “headaches” do not fall into the category of risk presented in the petition. The only  
17 risk presented in the petition was the risk of neurotoxic harm. *See F&WW II*, 302 F. Supp. 3d at  
18 1069–70. The physiological pain of headaches are merely a *symptom* and are described as  
19 symptoms in the study Plaintiffs attached to the petition. Headaches are altogether different from  
20 the other neurotoxic risks discussed in the petition, for example, reduced neurodevelopment of the  
21 brain, which is a source of injury and can be objectively measured. Plaintiffs needed to separately  
22 identify headaches in the petition itself if headaches are the only risk they suffer.

23 Even if the Court determines that Plaintiffs identified headaches as an unreasonable risk in  
24 their petition and that Plaintiffs have established a sufficient evidentiary basis that Ms. Simms and  
25 Kyle Adams experience headaches, all other individual and organizational Plaintiffs should be  
26 dismissed from this case. Plaintiffs have not attempted to demonstrate that any other Plaintiffs or  
27 declarants have suffered an unreasonable risk identified in the petition. Summary judgment is a  
28 time to narrow issues and parties for trial.

**B. Plaintiffs Lack Article III Standing**

Setting aside Plaintiffs' inability to demonstrate that they are exposed to the risks that they presented to EPA in their petition, Plaintiffs are unable to demonstrate that they suffered any injury caused by fluoridation chemicals in drinking water or that their injuries are redressable. EPA Br. 23–24. Plaintiffs claim that they suffer three types of injuries: reduction in well-being from avoiding fluoridation chemicals in drinking water, costs of avoiding fluoridation chemicals in drinking water, and fear of neurological harm in adults. The first two types rely on the substance of the third. Avoiding fluoridation chemicals in drinking water is not a cognizable harm unless there is a substantiated concern that drives this behavior. *Pennsylvania v. New Jersey*, 426 U.S. 660, 664 (1976). Otherwise, Plaintiffs' avoidance is not traceable to EPA's action. Plaintiffs attempted to demonstrate neurological injury to adults based on "Plaintiffs' first-hand experiences with headaches." Pls.' Opp'n 25. But Plaintiffs' experiences do not establish a genuine issue that fluoridation chemicals in U.S. drinking water cause headaches.

Even if headaches are a neurotoxic harm, the only study Plaintiffs cite in support of the relationship between fluoride and headaches *does not conclude* that low levels of fluoride, such as in U.S. fluoridated drinking water, cause headaches. Rather, the lowest exposure group consumed fluoridated water at levels at or below 1 mg/L. Pls.' Opp'n Ex. 46, at 1. By comparison, U.S. drinking water can be fluoridated to concentrations of 0.7 mg/L. The study tenuously concluded that fluoride "may cause various neurological manifestations among subjects" in the *highest* or "endemic" areas. *Id.* at 1, 131. But the study did not conclude that exposure to fluoride in the lowest exposure group had any effect on self-reported headaches.

And even if fluoridation chemicals could potentially cause headaches in the general population, Plaintiffs have not established that their declarants are at risk of headaches if they consume fluoridated water in the United States. Plaintiffs rely on Ms. Simms' declaration in which she claims to have experienced headaches after drinking fluoridated water. But Ms. Simms also admits that she experiences headaches when drinking un-fluoridated water, and that alcohol, lack of sleep, and aged cheese may also trigger her headaches. Simms Decl. ¶ 15. Further, she made other health changes at the same time she stopped drinking fluoridated drinking water, which may

1 explain any decrease in headaches. Simms Decl. ¶¶ 15, 17, 19. Plaintiffs also suggest that  
2 Mr. Adams experiences headaches when drinking fluoridated water. His mother reports that  
3 Mr. Adams complained of headaches in the morning, which “would inevitably seem to set in prior  
4 to leaving for work or starting his day.” Adams Decl. ¶ 11. She further claims that Mr. Adams  
5 would not experience these headaches while camping or after short, low-pressure showers of  
6 filtered, low-fluorine water. *Id.* ¶¶ 14–15. Because Plaintiffs have in no way isolated the effects of  
7 fluoridated drinking water on Mr. Adam’s headaches, as opposed to other factors like environment  
8 or time or pressure, their allegations that fluoridated water is the cause of the headaches is based  
9 on speculation, not facts. There is no science or data to support their claim that low concentrations  
10 of fluoride cause Ms. Simms’s or Mr. Adams’s purported headaches. These conclusory, self-  
11 serving declarations are not enough to support Plaintiffs’ burden.

12 Plaintiffs cite “the medical advice” in the form of notes of unverified authorship for  
13 Ms. Simms and Mr. Adams. Pls.’ Opp’n 25. The notes are inadmissible hearsay. Fed. R. Evid. 801.  
14 In any event, the notes regarding Ms. Simms do not provide any advice on fluoride but instead  
15 merely parrot Ms. Simms’ self-reported “history.” Pls.’ Opp’n Ex. 42 & 43. To the extent  
16 Mr. Adams’ post-litigation notes provide advice, despite Plaintiffs’ characterization of the notes  
17 as being from Mr. Adams’ treating “doctors,” Pls.’ Opp’n 20, one note is clearly not written by a  
18 medical doctor. Pls.’ Opp’n Ex. 45 (signed “ND”). Additionally, the notes do not reference any  
19 independent medical testing to confirm the declarants’ complaints that fluoridated drinking water  
20 was the cause of their symptoms. Conclusory notes are no better than other conclusory statements,  
21 and a “summary judgment motion cannot be defeated by relying solely on conclusory allegations  
22 unsupported by factual data.” *Taylor v. List*, 880 F.2d 1040, 1045 (9th Cir. 1989).

23 Finally, Plaintiffs cite the 2006 NRC study, Pls.’ Opp’n 25, which does discuss an animal  
24 study that may be of interest to those studying cognitive effects in the elderly, Pls.’ Opp’n Ex. 17,  
25 at 220, but the 2006 NRC study does not conclude that dementia is a risk of fluoride exposure.  
26  
27  
28

1 Even if Plaintiffs could cite other evidence on dementia,<sup>9</sup> they have no evidence that the level of  
2 fluoride in drinking water poses a risk of dementia. Moreover, not a single declarant can claim that  
3 dementia is an “actual or imminent” injury. *Lujan v. Defenders of Wildlife*, 504 U.S. 555, 564–65  
4 (1992). No declarant purported to be in the age group Plaintiffs claim is susceptible to dementia;  
5 no declarant claimed that they have an imminent fear of dementia; and no declarant provided  
6 evidence that exposure to fluoride at his or her age would lead to dementia. Their “some day” fears  
7 “do not support a finding of the ‘actual or imminent’ injury” required by case law. *Id.* at 565.

8 Plaintiffs have not shown that winning this case will redress their alleged injury. They also  
9 failed to establish that their individualized total intakes of fluoride would lead to injury. It is  
10 undisputed that declarants are exposed to fluoride from sources other than drinking water, and they  
11 have not accounted for the fluoride to which they are exposed from other sources. *See Wash. Env'tl.*  
12 *Council v. Bellon*, 732 F.3d 1131, 1141–42 (9th Cir. 2013) (standing demonstration is weak when  
13 there are multiple potential causes of injury). Plaintiffs have not established that eliminating  
14 fluoridated water would reduce their declarants’ exposure below the threshold of harm because  
15 their declarants will continue to be exposed to fluoride. And because Plaintiffs seek injunctive  
16 relief to remedy future harm, they must show “a very significant possibility of future harm; it is  
17 insufficient for them to demonstrate only a past injury.” *San Diego Cty. Gun Rights Comm. v.*  
18 *Reno*, 98 F.3d 1121, 1126 (9th Cir. 1996).

19 Any other neurological injury to other subpopulations is not of “imminent” and personal  
20 concern to Plaintiffs’ standing declarants. Plaintiffs have not shown that they have or will suffer  
21 injury from fluoridation chemicals, and, therefore, this case must be dismissed.

## 22 CONCLUSION

23 For each of the forgoing independent reasons, and the reasons stated in EPA’s Motion for  
24 Summary Judgment, and EPA’s Opposition to Plaintiffs’ Motion for Summary Judgment, the  
25 Court should grant EPA’s Motion for Summary Judgment.

---

26  
27 <sup>9</sup> Plaintiffs also cite an inadmissible 1999 union document that does not conclude that  
28 fluoride poses a risk of neurological harm in adults. Pls.’s Opp’n Ex. 14. Plaintiffs do not specify  
where in the document EPA scientists “proclaim[ed]” this risk to adults. Pls.’s Opp’n 24.

1 Date: October 24, 2019  
2 Washington, DC

3 Respectfully Submitted,

4 /s/ Brandon N. Adkins

5 Brandon N. Adkins

6 Debra J. Carfora

7 John Thomas H. Do

8 United States Department of Justice

9 Environment & Natural Resources Division

10 P.O. Box 7611

11 Washington, D.C. 20044

12 Tel: (202) 616-9174

13 Fax: (202) 514-8865

14 Email: brandon.adkins@usdoj.gov

**CERTIFICATE OF SERVICE**

I hereby certify that on this 24th day of October, 2019, a true and correct copy of the foregoing Defendant's Reply in Support of their Motion for Summary Judgment was filed electronically with the Clerk of the Court using CM/ECF. I also certify that the foregoing document is being served on all counsel of record via transmission of Notices of Electronic Filing generated by CM/ECF.

/s/ John Thomas H. Do  
John Thomas H. Do  
United States Department of Justice